
The biotech also raised $235 million in debt and equity funding to support marketing of the drop, which it claims to be an advance over existing treatments from AbbVie and others.

The biotech also raised $235 million in debt and equity funding to support marketing of the drop, which it claims to be an advance over existing treatments from AbbVie and others.